04 · Five things to know · 02
Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer
Must read
What happened
In a late-breaker at ENA 2026, Revolution Medicines reported updated Phase 1/2 data for Rasonque (daraxonrasib), 200 mg, with gemcitabine and nab-paclitaxel as first-line treatment for metastatic pancreatic cancer. In 61 patients followed for a median of 18.3 months, 60.7% had a confirmed response (95% CI 47.3 to 72.9). Complete responses were 8.2%. Median progression-free survival was 12.8 months and the 12-month overall survival rate 76.6%. The company called the safety consistent with the known profiles and gave no grade 3 or higher rates in its release. The randomized Phase 3 RASolute 303 is ongoing. Claim
Why it matters
FDA approved daraxonrasib on 08.26.2026 for metastatic pancreatic cancer after prior systemic therapy, or when multiagent therapy is not an option. These first-line numbers come from one arm with no comparator, so they cannot be set against chemotherapy alone. Analysis
What we’re watching
RASolute 303’s readout and the grade 3 or higher toxicity of the combination.
Claim CheckPartial
CLAIM CHECK
Partial The release gives no registry number. The matching study we found, NCT06445062, a platform trial, registers adverse events and dose-limiting toxicities as primaries for this combination; response and survival are secondaries.
Sources
Revolution Medicines release on GlobeNewswire, read through Investing News (11.19) (opens another website in a new tab) Co; NCT06445062 (opens another website in a new tab) Reg
Bookmarks need a Mind Club sign-in. How sign-in works
Read it in Five things to know